sequence stringlengths 4 17.9k | seq_id stringlengths 1 6 | pn stringclasses 996
values | title stringclasses 871
values | pbdt int64 20.2M 20.3M | status int64 1 225 ⌀ | family_country listlengths 1 55 | modified_info stringlengths 112 8.31k ⌀ |
|---|---|---|---|---|---|---|---|
ttcttcccttaatatttatca | 2023 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttcttcccttaatatttatca | 2023 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
ttcttcccttaatatttatca | 2023 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcagtttatatgtattcatga | 3035 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcagtttatatgtattcatga | 3035 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcagtttatatgtattcatga | 3035 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcagtttatatgtattcatga | 1970 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcagtttatatgtattcatga | 1970 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcagtttatatgtattcatga | 1970 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tacaagtgctcagttccaatgtg | 2860 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tacaagtgctcagttccaatgtg | 2860 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tacaagtgctcagttccaatgtg | 2860 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagggtatcaagactacgaacct | 654 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagggtatcaagactacgaacct | 654 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagggtatcaagactacgaacct | 654 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagggtatcaagactacgaacct | 204 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagggtatcaagactacgaacct | 204 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aagggtatcaagactacgaacct | 204 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 827 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 827 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 827 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 377 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 377 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 377 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 107 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 107 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 107 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 557 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 557 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tgttttggagcctacatagagaa | 557 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcgatcactgctgatggaagact | 1356 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcgatcactgctgatggaagact | 1356 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcgatcactgctgatggaagact | 1356 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcgatcactgctgatggaagact | 1082 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcgatcactgctgatggaagact | 1082 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcgatcactgctgatggaagact | 1082 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 256 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 256 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 256 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 706 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 706 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 706 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 2682 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 2682 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
aggaggaatgagtgactataagg | 2682 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 1143 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 1143 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 1143 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 725 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 725 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 725 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 275 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 275 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcggctttaccaaaacagttcag | 275 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 2590 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 2590 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 2590 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 2786 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 2786 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 2786 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 671 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 671 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 671 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 221 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 221 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 221 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 1110 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 1110 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gcccagtcatgacatttctcaaa | 1110 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 1905 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 1905 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 1905 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 3223 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 3223 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 3223 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 2970 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 2970 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 2970 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 2158 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 2158 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
actaccacttatttctaaata | 2158 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tggcatttcataagcctcattgt | 1509 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tggcatttcataagcctcattgt | 1509 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tggcatttcataagcctcattgt | 1509 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tggcatttcataagcctcattgt | 1766 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tggcatttcataagcctcattgt | 1766 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tggcatttcataagcctcattgt | 1766 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcttgtacgccatggaagagcag | 1347 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcttgtacgccatggaagagcag | 1347 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcttgtacgccatggaagagcag | 1347 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcttgtacgccatggaagagcag | 1073 | EP4221838A1 | Snca irna compositions and methods of use thereof for treating or preventing snca-associated neurodegenerative diseases | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcttgtacgccatggaagagcag | 1073 | EP4221838A1 | SNCA-IRNA-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG ODER PRÄVENTION VON SNCA-ASSOZIIERTEN NEURODEGENERATIVEN ERKRANKUNGEN | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
tcttgtacgccatggaagagcag | 1073 | EP4221838A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,230,809 | 1 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
taagatgagacactctttctggt | 19 | JP2024537202A | 急性肝性ポルフィリン症(AHP)のバイオマーカーとしての腎障害マーカー | 20,241,010 | 2 | [
"JP",
"US",
"EP",
"WO",
"TW"
] | [{"norInfos":[{"sourceData":"OTHER","norInfo":[{"modificationType":"Other"}]},{"sourceData":"Hydroxyl 2'-O-methyluridine phosphorothioate","norInfo":[{"modificationType":"Non natural base","modification":["um"]},{"modificationType":"Chemical","modification":["Phosphorothioate"]}]}],"locations":["1->1"],"infos":["OTHER"... |
taagatgagacactctttctggt | 14 | JP2024537202A | 急性肝性ポルフィリン症(AHP)のバイオマーカーとしての腎障害マーカー | 20,241,010 | 2 | [
"JP",
"US",
"EP",
"WO",
"TW"
] | [{"infos":["OTHER"],"locations":["16->16"],"norInfos":[{"norInfo":[{"modificationType":"Other"}],"sourceData":"OTHER"}]}] |
gugacuaccacuuauuucuaa | 1446 | WO2022072447A1 | SNCA IRNA compositions and methods of use thereof for treating or preventing SNCA-associated neurodegenerative diseases | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gugacuaccacuuauuucuaa | 1446 | WO2022072447A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gugacuaccacuuauuucuaa | 324 | WO2022072447A1 | SNCA IRNA compositions and methods of use thereof for treating or preventing SNCA-associated neurodegenerative diseases | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gugacuaccacuuauuucuaa | 324 | WO2022072447A1 | COMPOSITIONS À BASE D'ARNI DE SNCA ET LEURS PROCÉDÉS D'UTILISATION POUR TRAITER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES ASSOCIÉES À SNCA | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
gugacuaccacuuauuucuaa | 2968 | WO2022072447A1 | SNCA IRNA compositions and methods of use thereof for treating or preventing SNCA-associated neurodegenerative diseases | 20,220,407 | 224 | [
"CN",
"HK",
"JP",
"IN",
"SG",
"IL",
"TW",
"KR",
"US",
"EA",
"BR",
"MX",
"EP",
"CA",
"ZA",
"WO",
"NZ",
"AU",
"AR"
] | null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.